Search
Seladelpar
go.drugbank.com/drugs/DB12390ApprovedInvestigationalSeladelpar is a peroxisome proliferator-activated receptor (PPAR)-delta (δ) agonist. Seladelpar is a single enantiomer of the R-configuration. … [L51149] On August 14, 2024, seladelpar was granted accelerated approval by the FDA for the treatment of primary biliary cholangitis,[L51154] which is a condition associated with aberrant bile acid metabolism
Synonyms: (R)-2-(4-((2-ETHOXY-3-(4-(TRIFLUOROMETHYL)PHENOXY)PROPYL)-THIO)-2-METHYLPHENOXY)ACETIC ACID, ((4-(((2R)-2-ETHOXY-3-(4-(TRIFLUOROMETHYL)PHENOXY)PROPYL)THIO)-2-METHYLPHENYL)OXY)ACETIC ACIDCategories: P-glycoprotein substrates, Cytochrome P-450 SubstratesRemimazolam
go.drugbank.com/drugs/DB12404ApprovedInvestigational[L14647] Recent trends in anesthesia-related drug development have touted the benefits of so-called "soft drugs" - these agents, such as [remifentanil], are designed to be metabolically fragile and thus … [A214857] These "soft drugs" are useful in the context of surgical procedures, wherein a rapid onset/offset is desirable, enabling anesthesiologists to manipulate drug concentrations as needed.
Categories: Heterocyclic Compounds, 2-RingNadifloxacin
go.drugbank.com/drugs/DB12447InvestigationalNadifloxacin has been used in trials studying the treatment of Acne Vulgaris.
Categories: 4-Quinolones, Heterocyclic Compounds, 2-RingProducts: MAGNIS %1 KREM ,30 G, AKNEFLOKS %1 KREM, 30 GRimegepant
go.drugbank.com/drugs/DB12457ApprovedInvestigationalRimegepant is an oral antagonist of the CGRP receptor developed by Biohaven Pharmaceuticals. … [A189207] Antagonism of the CGRP pathway has become an attractive target for migraine therapy as, unlike the triptans, oral CGRP antagonists have no observed vasoconstrictive properties and are therefore
Categories: MATE 1 Inhibitors, P-glycoprotein substratesFedratinib
go.drugbank.com/drugs/DB12500ApprovedInvestigationalFedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis. … [A183176,L8090] It is an anilinopyrimidine derivative.[A183188] Fedratinib was granted FDA approval on August 16, 2019.[L8090]
Categories: MATE 1 Inhibitors, MATE 2 InhibitorsOmaveloxolone
go.drugbank.com/drugs/DB12513ApprovedInvestigational[A257534,A257539] Omaveloxolone acts as an activator of nuclear factor (erythroid-derived 2)-like 2 (Nrf2), a transcription factor that mitigates oxidative stress. … In patients with Friedreich's ataxia, a genetic disease involving mitochondrial dysfunction, the Nrf2 pathway is impaired, and Nrf2 activity is lower.
Synonyms: Propanamide, N-(2-cyano-3,12-dioxo-28-noroleana-1,9(11)-dien-17-yl)-2,2-difluoro-Categories: Cytochrome P-450 CYP2C8 Inducers, Cytochrome P-450 SubstratesBatefenterol
go.drugbank.com/drugs/DB12526InvestigationalBatefenterol has been used in trials studying the treatment of Pulmonary Disease, Chronic Obstructive.
Categories: Heterocyclic Compounds, 2-Ring, Adrenergic beta-2 Receptor AgonistsTradipitant
go.drugbank.com/drugs/DB12580ApprovedInvestigationalTradipitant is a selective, high-affinity antagonist at human substance P/neurokinin-1 (NK-1) receptors. … [A275353] Approved by the FDA on December 30, 2025, tradipitant is indicated for the prevention of vomiting induced by motion.
Synonyms: (2-(1-(3,5-BIS(TRIFLUOROMETHYL)BENZYL)-5-PYRIDIN-4-YL-1H-1,2,3-TRIAZOL-4-YL)PYRIDIN-3-YL)(2-CHLOROPHENYL)METHANONE, METHANONE, (2-(1-((3,5-BIS(TRIFLUOROMETHYL)PHENYL)METHYL)-5-(4-PYRIDINYL)-1H-1,2,3-TRIAZOL-4-YL)-3-PYRIDINYL)(2-CHLOROPHENYL)-Categories: Substance P/Neurokinin-1 Receptor Antagonist, P-glycoprotein substratesAsciminib
go.drugbank.com/drugs/DB12597ApprovedInvestigationalMore specifically, it is an inhibitor of the ABL1 kinase activity of the BCR-ABL1 fusion protein[L38995] which serves as a driver of CML proliferation in most patients with the disease. … [L39005] It has also shown benefit in Ph+ CML with the T315I mutation, which produces a mutant BCR-ABL1 which is typically treatment-resistant as compared to wild-type BCR-ABL1.
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesSisomicin
go.drugbank.com/drugs/DB12604InvestigationalSisomicin has been used in trials studying the treatment of Pyoderma.
Synonyms: (2S-CIS)-4-O-(3-AMINO-6-(AMINOMETHYL)-3,4-DIHYDRO-2H-PYRAN-2-YL)-2-DEOXY-6-O-(3-DEOXY-4-C-METHYL-3-(METHYLAMINO)-.BETA.-L-ARABINOPYRANOSYL)-D-STREPTAMINE, O-3-DEOXY-4-C-METHYL-3-(METHYLAMINO)-.BETA-L-ARABINOPYRANOSYL-(1->4)-O-(2,6-DIAMINO-2,3,4,6-TETRADEOXY-.ALPHA.-D-GLYCERO-HEX-4-ENOPYRANOSYL-(1->6))-2-DEOXY-L-STREPTAMINECategories: Drugs that are Mainly Renally Excreted with a Narrow Therapeutic Index